Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12MG)

What Is the Tesamorelin & CJC-1295 & Ipamorelin Blend?

The Tesamorelin & CJC-1295 & Ipamorelin Blend is a 12mg research peptide formulation combining three complementary growth hormone secretagogues: Tesamorelin (4mg), a full-length 44-amino acid GHRH(1-44) analog with N-terminal trans-3-hexenoyl modification for enhanced stability; CJC-1295 (4mg), a 29-amino acid GHRH analog also known as Modified GRF 1-29; and Ipamorelin (4mg), a highly selective synthetic pentapeptide ghrelin receptor agonist. For those looking to buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland, Core Peptides offers high-quality research-grade material for laboratory applications.

This triple blend pairs two GHRH analogues with a selective ghrelin receptor agonist, studied for synergistic amplification of growth hormone release through dual pituitary receptor pathway activation. Tesamorelin is the only GHRH analogue with FDA approval (HIV-associated lipodystrophy, 2 mg/day subcutaneous) and multiple positive human RCTs, giving it the strongest evidence base in this blend category. CJC-1295 (without DAC) has a half-life of roughly 30 minutes, preserving pulsatility, while CJC-1295 with DAC has a half-life of roughly 8 days and produces continuous GH elevation. Ipamorelin is the most specific and selective ghrelin receptor agonist known, activating GHS-R1a without significantly affecting cortisol, prolactin, or ACTH levels at research doses. This selectivity distinguishes the Tesamorelin/CJC-1295/Ipamorelin combination from blends using less selective GHRPs such as GHRP-6 or GHRP-2.

Research Overview

The Tesamorelin & CJC-1295 & Ipamorelin Blend has attracted research interest as a triple-pathway approach to investigating growth hormone axis physiology. Tesamorelin is a synthetic 44-amino acid peptide corresponding to the full-length sequence of endogenous human growth hormone-releasing hormone (GHRH(1-44)). CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) that mimics and amplifies the signal to the pituitary gland to release growth hormone. Meanwhile, Ipamorelin is a pentapeptide categorized as a selective growth hormone secretagogue that interacts with ghrelin receptors in the anterior pituitary.

Research interest in this blend centers on the synergistic interaction between these pathways. Tesamorelin and CJC-1295 act as GHRH receptor agonists, while Ipamorelin acts through a distinct GHS-R1a pathway. Because these two systems converge on GH release through different intracellular pathways, they produce synergistic (not merely additive) effects when activated simultaneously. Their distinct mechanisms of action may complement each other, potentially amplifying growth hormone release and its downstream impacts on cellular functions. Consequently, this triple blend has generated significant interest as a research tool for investigating growth hormone physiology, pituitary function, and the hypothalamic-pituitary-somatotroph axis.

When researchers choose to buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland for laboratory studies, they gain access to a compound that may help elucidate mechanisms of synergistic GH secretion, dual GPCR signaling convergence, and growth hormone regulation at the molecular level.

How Does the Triple Blend Work?

The Tesamorelin & CJC-1295 & Ipamorelin Blend exerts its biological effects through simultaneous activation of two distinct pituitary receptor pathways that converge on somatotroph cells to amplify growth hormone release.

Tesamorelin and CJC-1295: GHRH Receptor Activation

Tesamorelin and CJC-1295 mimic endogenous GHRH by binding to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs.

CJC-1295 binds to GHRH receptors on the pituitary gland, stimulating the release of growth hormone in pulses that preserve the body’s natural GH rhythm. This class B GPCR activates the Gs/adenylyl cyclase/cAMP/PKA cascade. PKA then phosphorylates L-type calcium channels and the CREB transcription factor. This simultaneously triggers acute GH release and stimulates GH gene transcription. Importantly, this preserves normal GH pulsatility and feedback regulation.

Tesamorelin incorporates a critical structural modification: a trans-3-hexenoic acid group attached to the N-terminus. This hexenoyl cap shields the peptide from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), roughly tripling its plasma persistence without altering its receptor binding profile. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes, preserving pulsatility, while CJC-1295 with DAC has a half-life of roughly 8 days.

Ipamorelin: Ghrelin Receptor Activation

Ipamorelin acts as an agonist of the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). This Gq-coupled receptor activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes endoplasmic reticulum calcium stores, releasing Ca²⁺ into the cytoplasm. Meanwhile, DAG activates protein kinase C (PKC), which interacts with protein synthesis related to GH synthesis.

Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. Unlike earlier compounds in its category, Ipamorelin appears to display a more targeted interaction profile, minimizing engagement with other endocrine pathways. Research indicates that Ipamorelin may stimulate growth hormone release through a mechanism distinct from GHRH analogs, thereby offering a complementary signaling route. Ipamorelin is more selective, raising GH without elevating adrenocorticotropic hormone (ACTH)/cortisol.

Synergistic Amplification

The triple blend exploits dual signaling convergence on somatotroph calcium levels. Tesamorelin- and CJC-1295-mediated cAMP/PKA signaling sensitizes voltage-gated calcium channels. At the same time, Ipamorelin-mediated IP₃/PKC signaling mobilizes intracellular calcium. The convergent activation of these distinct receptor systems on the same somatotroph cell produces synergistic GH pulse amplification.

When researchers administer these peptides together, they stimulate the pituitary gland through multiple pathways, resulting in a significantly amplified and more sustained release of growth hormone compared to any single peptide alone. Importantly, this triple mechanism preserves the physiological pulsatile pattern of GH release and maintains negative feedback via IGF-1 and somatostatin, distinguishing it from exogenous GH administration. Rather than producing a linear increase in hormone levels, the blend supports a pattern that more closely resembles endogenous secretion cycles.

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland for research purposes can investigate these mechanisms across diverse experimental models of growth hormone physiology and pituitary function.

Why Is This Triple Blend Studied?

Researchers study the Tesamorelin & CJC-1295 & Ipamorelin Blend primarily for its potential relevance to growth hormone physiology, pituitary function, and the hypothalamic-pituitary-somatotroph axis. The synergistic amplification of GH release through complementary pathways makes it a valuable tool for understanding the molecular basis of GH regulation.

Tesamorelin has been extensively studied in the context of metabolic research, particularly for its effects on visceral adipose tissue. In HIV-infected patients with lipodystrophy, Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue (VAT) and improving body composition. Tesamorelin is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Research has also explored its effects on hepatic fat, lean body mass, and IGF-1 levels.

CJC-1295 has demonstrated dose-dependent, sustained increases in both GH and IGF-1 levels in healthy adults, with no observed desensitization of the pituitary gland over time. Elevated GH levels increase lipolysis (fat breakdown) while preserving lean muscle mass.

Moreover, researchers study Ipamorelin in the context of selective GH release without significant cortisol or prolactin elevation. Studies showed that ipamorelin was the first GHRP not to stimulate cortisol significantly. This selectivity makes Ipamorelin a valuable tool for investigating GH release pathways without confounding hormonal effects.

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides can incorporate this peptide into their studies on GHRH receptor signaling, ghrelin receptor pharmacology, somatotroph function, and growth hormone physiology.

Research Areas

Research Area	Description
Synergistic GH Release	Investigating the combined effects of GHRH analogs (Tesamorelin, CJC-1295) and Ipamorelin on GH secretion
GHRH Receptor Pharmacology	Studying Tesamorelin and CJC-1295 binding and activation of GHRH-R on somatotrophs
Ghrelin Receptor (GHS-R1a) Studies	Examining Ipamorelin’s selective activation of the ghrelin receptor
cAMP/PKA Signaling	Investigating the cAMP pathway activated by GHRH analogs
PLC/IP3/DAG Pathway	Exploring the phospholipase C pathway activated by Ipamorelin
Somatotroph Function	Studying the effects of triple pathway activation on pituitary somatotroph cells
Growth Hormone Physiology	Exploring pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis
Metabolic Research	Investigating effects on visceral adipose tissue, lipid metabolism, and body composition

Scientific Research

Researchers have conducted scientific studies on Tesamorelin, CJC-1295, Ipamorelin, and their combinations in both in vitro and in vivo settings. They have derived evidence from cell cultures, preclinical models, and clinical research.

Tesamorelin Evidence

Tesamorelin has been extensively studied in human clinical research. The FDA initially approved Tesamorelin (Egrifta) in November 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In HIV-associated lipodystrophy, a meta-analysis of four randomized controlled trials (909 patients) demonstrated that Tesamorelin 2mg significantly reduced visceral adipose tissue.

In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. Tesamorelin is the only GHRH analogue with an FDA approval and multiple positive human RCTs, giving it the strongest evidence base in this stack category.

CJC-1295 Evidence

CJC-1295 has been studied in human clinical trials, including studies in The Journal of Clinical Endocrinology and Metabolism, demonstrating that even low weekly doses of CJC-1295 produce dose-dependent, sustained increases in both GH and IGF-1 levels in healthy adults. Published Phase 1 and Phase 2 human trials have confirmed these findings.

One study identified CJC-1295 as a stable and active hGRF1-29 analog with an extended plasma half-life. CJC-1295 without DAC (also called Modified GRF 1-29) has a shorter half-life than the DAC-conjugated version in the blood.

Ipamorelin Evidence

Ipamorelin has been characterized as the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. A pharmacological profiling using GHRP and GHRH antagonists clearly demonstrated that ipamorelin stimulates GH release via a GHRP-like receptor. Early studies showed that ipamorelin was the first GHRP not to stimulate cortisol significantly.

Nevertheless, researchers should note that Ipamorelin’s synergy with GHRH analogues is supported by animal and mechanistic data but has not been confirmed in a published human RCT as a combination. This blend is supplied for laboratory research purposes only. Scientists who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland should remain aware of these evidence considerations.

Compared With Related Peptides

Peptide/Blend	Relationship	Key Differences
Tesamorelin Alone	Single component of the blend	Tesamorelin alone activates only GHRH-R; the blend adds CJC-1295 and Ipamorelin for synergistic amplification
CJC-1295 Alone	Single component of the blend	CJC-1295 alone activates only GHRH-R; the blend adds Tesamorelin and Ipamorelin
Ipamorelin Alone	Single component of the blend	Ipamorelin alone activates only GHS-R1a; the blend adds two GHRH analogs for synergistic amplification
Sermorelin & GHRP-2 Blend	Both are GHRH + GHRP blends	GHRP-2 is less selective; Ipamorelin is highly selective with minimal off-target effects; Tesamorelin is FDA-approved
Growth Hormone (GH)	Blend stimulates endogenous GH	GH is direct exogenous administration; the blend stimulates natural pulsatile GH release

Research Applications

Researchers utilize the Tesamorelin & CJC-1295 & Ipamorelin Blend in a variety of laboratory research applications, primarily in the fields of endocrinology, receptor pharmacology, and growth hormone physiology. Key research applications include:

• Synergistic GH Release Studies: Investigating the combined effects of GHRH analogs (Tesamorelin, CJC-1295) and Ipamorelin on GH secretion
• GHRH Receptor Studies: Studying Tesamorelin and CJC-1295 binding and activation of GHRH-R on somatotrophs
• Ghrelin Receptor (GHS-R1a) Studies: Examining Ipamorelin’s selective activation of the ghrelin receptor
• cAMP/PKA Signaling Research: Investigating the cAMP pathway activated by GHRH analogs
• PLC/IP3/DAG Pathway Research: Exploring the phospholipase C pathway activated by Ipamorelin
• Somatotroph Function Studies: Studying the effects of triple pathway activation on pituitary somatotroph cells
• Growth Hormone Physiology Research: Exploring pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis
• Metabolic Research: Investigating effects on visceral adipose tissue, lipid metabolism, and body composition

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland can incorporate this peptide into their experimental protocols across these diverse research areas.

Product Specifications

Specification	Detail
Product Name	Tesamorelin & CJC-1295 & Ipamorelin Blend
Total Amount	12mg
Contents	Tesamorelin (4mg) & CJC-1295 (4mg) & Ipamorelin (4mg)
Form	Lyophilized powder
Purity	>99% (HPLC)
Tesamorelin Sequence (One-Letter)	trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
Tesamorelin Molecular Formula	C221H366N72O67S
Tesamorelin Molecular Weight	Approximately 5,135.8 g/mol
Tesamorelin CAS Number	218949-48-5
CJC-1295 Sequence (One-Letter)	H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
CJC-1295 Molecular Formula	C152H252N44O42
CJC-1295 Molecular Weight	Approximately 3,367.9 g/mol
CJC-1295 CAS Number	446262-90-4 (with DAC)
Ipamorelin Sequence (One-Letter)	Aib-His-D-2-Nal-D-Phe-Lys-NH2
Ipamorelin Molecular Formula	C38H49N9O5
Ipamorelin Molecular Weight	Approximately 711.9 g/mol
Ipamorelin CAS Number	170851-70-4
Ipamorelin Synonyms	NNC 26-0161
Mechanism	GHRH receptor agonists (Tesamorelin, CJC-1295) + GHS-R1a agonist (Ipamorelin); synergistic GH release
Research Category	Growth Hormone Blends
SKU	P-TES-CJC-IPA-12
Storage	Store desiccated at -20°C, protected from light

How to Evaluate Quality

When sourcing the Tesamorelin & CJC-1295 & Ipamorelin Blend for research purposes, researchers should consider several quality indicators. A reliable Tesamorelin & CJC-1295 & Ipamorelin Blend peptide supplier should provide:

• Identity Confirmation: Analytical verification that all three peptides match their expected sequences and molecular weights
• Purity Analysis: Documentation of purity through methods such as HPLC – research grade typically provides >99% purity
• Batch Information: Clear lot numbers and batch traceability
• Certificate of Analysis (CoA): Documentation of analytical testing results
• Proper Labeling: Accurate product identification and storage instructions
• Appearance: White to off-white lyophilized powder

Researchers looking to buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland should seek suppliers who provide comprehensive documentation and quality assurance. Core Peptides remains committed to supporting research with properly documented products.

Understanding the Certificate of Analysis

A Certificate of Analysis (CoA) provides analytical data for a specific batch of a research peptide. For Tesamorelin & CJC-1295 & Ipamorelin Blend research, a CoA typically includes:

• Identity Confirmation: Mass spectrometry confirming all three peptides’ identities
• Purity Assessment: HPLC chromatograms showing the purity of each peptide
• Batch/Lot Information: Unique identifiers for traceability
• Analytical Methods: Description of the testing methods used

Importantly, researchers should understand that a CoA demonstrates the chemical identity and purity of a peptide but does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. The CoA serves as a quality control document for research purposes only.

Storage and Stability

Proper storage of research peptides is essential for maintaining their integrity and stability. For Tesamorelin & CJC-1295 & Ipamorelin Blend, researchers should refer to the product documentation provided with their order for specific storage recommendations.

General best practices for peptide storage include keeping the lyophilized blend desiccated, protected from light, and stored at -20°C or below. For specific temperature requirements and reconstitution protocols, consult the applicable product documentation or contact Core Peptides for the applicable storage specifications.

Research Considerations

Researchers incorporating the Tesamorelin & CJC-1295 & Ipamorelin Blend into their studies should be aware of several important considerations:

• Clinical Status: Tesamorelin has been extensively studied in human clinical research and received FDA approval in 2010 for HIV-associated lipodystrophy. CJC-1295 has been studied in Phase 1 and Phase 2 human trials. However, the blend is supplied for laboratory research purposes only.
• Experimental Status: Researchers consider the blend a well-characterized combination, but findings should be interpreted within the context of ongoing research.
• Model Differences: Results from cell cultures and animal models may not translate directly to human outcomes.
• Regulatory Status: All components are not FDA-approved for research applications and are intended for laboratory research use only.
• Quality Considerations: Researchers should verify the quality and identity of their blend through appropriate analytical methods.
• Mechanistic Context: The blend’s proposed mechanisms involve GHRH receptor activation, ghrelin receptor activation, and synergistic signaling convergence. Researchers should consider appropriate experimental approaches to investigate these pathways.
• Selectivity Profile: Ipamorelin is distinguished by its high selectivity for GHS-R1a without significant effects on cortisol, prolactin, or ACTH, making this blend the most selective triple-pathway GH secretagogue combination available.
• Combination Synergy: Ipamorelin’s synergy with GHRH analogues is supported by animal and mechanistic data but has not been confirmed in a published human RCT as a combination.

Researchers who buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland should ensure their studies include appropriate controls and interpret findings with scientific rigor.

Frequently Asked Questions

What is the Tesamorelin & CJC-1295 & Ipamorelin Blend?

The Tesamorelin & CJC-1295 & Ipamorelin Blend is a 12mg research peptide combination containing Tesamorelin (4mg), a full-length GHRH(1-44) analog; CJC-1295 (4mg), a GHRH analog (Mod GRF 1-29); and Ipamorelin (4mg), a highly selective ghrelin receptor agonist.

What is this blend researched for?

Researchers primarily investigate this blend for synergistic amplification of growth hormone release through dual pituitary receptor pathway activation.

What is the mechanism of action?

Tesamorelin and CJC-1295 activate GHRH receptors via the cAMP/PKA cascade, while Ipamorelin targets GHS-R1a via the PLC/IP3/DAG pathway. Together, they produce synergistic GH release greater than any peptide alone.

What is the molecular weight of each component?

Tesamorelin has a molecular weight of approximately 5,135.8 g/mol. CJC-1295 has a molecular weight of approximately 3,367.9 g/mol. Ipamorelin has a molecular weight of approximately 711.9 g/mol.

What are the CAS numbers?

Tesamorelin CAS: 218949-48-5. CJC-1295 CAS: 446262-90-4 (with DAC). Ipamorelin CAS: 170851-70-4.

Is this blend FDA-approved?

This blend is not FDA-approved. It is intended for laboratory research use only and is not approved for human consumption or therapeutic use.

Can I buy the Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland?

Yes, researchers can buy Tesamorelin & CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides for laboratory research purposes.

What is the primary research category for this blend?

This blend belongs to the Growth Hormone Blends category, with secondary relevance to Cellular Research & Signaling.

What related peptides are studied alongside this blend?

Related peptides include Tesamorelin alone, CJC-1295 alone, Ipamorelin alone, Sermorelin, GHRP-2, and other growth hormone secretagogues.

What is the purity of Core Peptides’ blend?

Core Peptides provides this blend with a purity of >99% as verified by HPLC analysis.

How should the blend be stored?

The blend should be stored lyophilized, desiccated, protected from light, at -20°C or below.

Does this blend preserve natural GH pulsatility?

Yes, unlike direct GH administration, this blend stimulates the pituitary to produce and secrete GH, preserving the natural pulsatile release pattern and maintaining negative feedback.

What distinguishes Ipamorelin from other GHRPs?

Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH, without significantly affecting cortisol, prolactin, or ACTH levels.

Related Research Peptides

Researchers interested in the Tesamorelin & CJC-1295 & Ipamorelin Blend may also find the following related peptides relevant to their work:

• Tesamorelin – The full-length GHRH(1-44) analog component, studied for GHRH receptor research
• CJC-1295 – The GHRH analog (Mod GRF 1-29) component, studied for GHRH receptor research
• Ipamorelin – The selective ghrelin receptor agonist component, studied for GHS-R1a research
• Sermorelin – A 29-amino acid GHRH fragment (GHRH 1-29) studied for GHRH receptor research
• Growth Hormone – The downstream hormone regulated by GHRH and GHRP signaling

For a comprehensive selection of research peptides in Switzerland, explore the Core Peptides catalog.

Explore Growth Hormone Blends

The Tesamorelin & CJC-1295 & Ipamorelin Blend is part of our Growth Hormone Blends category, which features pre-mixed combinations of research peptides for growth hormone axis studies. Browse our selection to find the right peptides for your laboratory research.

Explore Related Research Categories

Researchers may also find the following related categories relevant to this blend:

• Cellular Research & Signaling – Peptides studied for GPCR signaling and receptor pharmacology
• Growth Hormone Peptides – Individual peptides for growth hormone research
• Anti-Aging & Longevity – Peptides investigated for age-related endocrine research

Further Research

Researchers interested in learning more about the Tesamorelin & CJC-1295 & Ipamorelin Blend and related peptides should consult the primary scientific literature. Key areas of investigation include GHRH receptor biology, ghrelin receptor pharmacology, synergistic GH release, and growth hormone physiology. The PubMed database is an excellent resource for accessing peer-reviewed research articles on these topics.

Research Disclaimer

Core Peptides supplies the Tesamorelin & CJC-1295 & Ipamorelin Blend as a research peptide for laboratory research purposes only. It is not approved for human consumption, therapeutic use, or medical treatment. All information provided is for educational and scientific reference purposes only and does not constitute medical advice. Researchers are responsible for ensuring compliance with all applicable laws and regulations governing the use of research peptides in their jurisdiction, including Switzerland.